# PAQ Therapeutics

> PAQ Therapeutics is a clinical-stage biotechnology company in Burlington, Massachusetts developing a new class of small-molecule degraders that harness autophagy, the body's natural cellular recycling system, to destroy disease-causing proteins. Its proprietary ATTEC (autophagosome-tethering compound) platform aims to eliminate targets that traditional inhibitors cannot reach. The company's lead programs are KRAS degraders - PT0253, a selective KRAS G12D degrader, and PT0511, a pan-KRAS degrader - both in Phase 1 clinical trials for lung, colorectal and pancreatic cancers driven by KRAS mutations.

- **Founded:** 2020
- **Headquarters:** Burlington, Massachusetts, United States
- **Founders:** Nan Ji (Co-Founder, President & CEO), Huaixiang Hao (Co-Founder, Head of Research), Boxun Lu (Scientific Co-Founder (Professor, Fudan University))
- **Team size:** ~12 employees
- **Products:** ATTEC Platform, PT0253, PT0511
- **Notable:** Built a first-in-class ATTEC (autophagosome-tethering compound) degradation platform., Advanced two KRAS degraders (PT0253, PT0511) into Phase 1 clinical trials., Raised $111M in total funding across Seed, Series A and Series B.

## Products & services

- **ATTEC Platform** — Autophagosome-tethering compounds: small molecules that selectively tether disease-causing substrates (proteins, aggregates, lipids, mitochondria, pathogens) to the autophagy machinery for degradation.
- **PT0253** — A potent, selective KRAS G12D degrader with best-in-class preclinical potential; lead oncology candidate, first patient dosed in Phase 1 in Q1 2025.
- **PT0511** — A pan-KRAS degrader targeting a broad range of KRAS mutations; first patient dosed in Phase 1 in January 2026.

## Achievements

- Built a first-in-class ATTEC (autophagosome-tethering compound) degradation platform.
- Advanced two KRAS degraders (PT0253, PT0511) into Phase 1 clinical trials.
- Raised $111M in total funding across Seed, Series A and Series B.
- Attracted investment from Merck's and Johnson & Johnson's venture arms.
- Founder Nan Ji has filed 30+ patent applications across degradation chemistry.

## Latest updates

- **2026-01** — First patient dosed in Phase 1 clinical study of PT0511, PAQ's pan-KRAS degrader.
- **2025-05** — Announced $39M Series B financing co-led by MRL Ventures Fund and Bayland Capital and initiated Phase 1 trial of PT0253.
- **2025-Q1** — First patient dosed in Phase 1 study of lead candidate PT0253, a selective KRAS G12D degrader.
- **2021-09** — Announced AI drug-discovery collaboration with Insilico Medicine.
- **2021-07** — Launched publicly with a $30M Series A financing led by Sherpa Healthcare Partners.

## Links

- Website: https://paqtx.com
- LinkedIn: https://www.linkedin.com/company/paq-therapeutics

---

Profile page: https://yespress.io/paq-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-18